Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 10 recruiting now early-phase tilt

Primary Open Angle Glaucoma: early-phase trial registry

10 of 20 indexed Primary Open Angle Glaucoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #848 of 28,707 conditions by registered trial count.

20 US clinical trials · 10 currently recruiting · #848 of 28,707 conditions by registered trial count

Primary Open Angle Glaucoma: 20 US clinical trials tracked, 10 recruiting.

Primary Open Angle Glaucoma is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is University of Alabama at Birmingham, running 2 of these trials.

Enrollment posture brief

Registry condition primary-open-angle-glaucoma

OPEN 10 | RECR 50% | LATE 1 | EARLY 7 | RANK #848 | SPON 2

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Advanced or Metastatic Solid55%ALS50%Primary Open Angle Glauc (th…50%Abdominal Pain25%Acute Myocardial Infarction25%
Open-enrollment share among volume-matched conditions near Primary Open Angle Glaucoma

Primary Open Angle Glaucoma lists 10 open slots (50% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Primary Open Angle Glaucoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Primary Open Angle Glaucoma is recruiting above its size-band peers.

    10 of 20 indexed trials (50%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Primary Open Angle Glaucoma trials is spread across many organizations.

    University of Alabama at Birmingham accounts for 2 of 20 trials (10%). 19 distinct sponsors appear on at least one study for this condition label.

  3. Typical Primary Open Angle Glaucoma enrolment sits around 129 participants.

    Median target enrolment is 129 among the 20 trials that report a genuine target (sentinel values excluded). 8 of those (40%) plan for fewer than 100 participants.

  4. Primary Open Angle Glaucoma research is mostly interventional.

    14 interventional and 6 observational studies make up this index (70% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 27Phase 31

Open and recent trials

20 total, page 1 of 1

RECRUITING 3,000 participants

Diagnostic Innovations in Glaucoma Study

University of California, San Diego

NCT00221897

RECRUITING NA 545 participants

Hydrus® Microstent New Enrollment Post-Approval Study

Alcon Research

NCT04553523

RECRUITING Phase 3 130 participants

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

AbbVie

NCT06822738

RECRUITING NA 129 participants

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

Sanoculis

NCT06313749

RECRUITING 100 participants

Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults

University of Alabama at Birmingham

NCT04396002

RECRUITING NA 78 participants

Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma

Nova Eye

NCT05564091

RECRUITING 60 participants

DSLT for Reducing Medication in Glaucoma

The Eye Institute of West Florida

NCT07390890

RECRUITING 60 participants

A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients

Brian Shafer

NCT07076303

RECRUITING Phase 2 50 participants

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

Amydis

NCT06223048

RECRUITING NA 30 participants

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

59th Medical Wing

NCT05844384

ACTIVE NOT RECRUITING Phase 2 250 participants

Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study

Columbia University

NCT05695027

ACTIVE NOT RECRUITING 150 participants

Advanced Glaucoma Progression Study

University of California, Los Angeles

NCT01742819

ACTIVE NOT RECRUITING 88 participants

Impact of Glaucoma and Visual Field Loss on Life Space

University of Alabama at Birmingham

NCT03673644

COMPLETED Phase 2 194 participants

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

EyePoint Pharmaceuticals

NCT04405245

COMPLETED Phase 2 176 participants

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

Bausch & Lomb Incorporated

NCT00441883

COMPLETED Phase 2 163 participants

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Allergan

NCT01110499

COMPLETED NA 152 participants

Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes

Ivantis

NCT02023242

COMPLETED Phase 2 119 participants

Ahmed Glaucoma Valve Surgery With Mitomycin-C

University of California, San Francisco

NCT02805257

COMPLETED Phase 2 84 participants

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

Qlaris Bio

NCT04830397

COMPLETED NA 35 participants

The Effects of Visior on Ocular Hemodynamics

Visior Technologies

NCT02959593

Phase Distribution

PhaseTrial count
Phase 2 7
Phase 3 1

Top Sponsors

Ivantis 1 trials
Allergan 1 trials
Nova Eye 1 trials
Sanoculis 1 trials
Brian Shafer 1 trials
Qlaris Bio 1 trials

Named interventions

Most-linked intervention names on Primary Open Angle Glaucoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cataract surgery Procedure
2 trials
Hydrus Microstent Device
2 trials
Placebo Drug
2 trials
VISIOR video goggles Device
1 trials
QLS-101 Drug
1 trials
Timolol Maleate Drug
1 trials
AGN-210961 Formulation 5 Drug
1 trials
AGN-210961 Formulation 4 Drug
1 trials

US sites by state

Facility locations filed on Primary Open Angle Glaucoma trials. A trial with sites in several states counts in each.

California 11 trials
Texas 6 trials
Pennsylvania 5 trials
Georgia 4 trials
Florida 4 trials
Oklahoma 3 trials
New York 3 trials
North Carolina 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Primary Open Angle Glaucoma page

20 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Open Angle Glaucoma condition card totals 20 registered trials; most-linked intervention Cataract surgery; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.